offer
all report title image
  • Published On : Apr 2022
  • Code : CMI5000
  • Industry : Pharmaceutical
  • Pages : 185
  • Formats :

Suboxone is a medicine used to treat opioid (narcotic) drug dependence of drugs such as heroin or morphine in drug addicts.  Suboxone is given to adults and children over the age of 15 who are also seeking medical, social, and psychological care. Suboxone has two active ingredients - buprenorphine and naloxone. Buprenorphine is a partial opioid agonist, which means it functions similarly to an opioid. Naloxone is an opioid antagonist, which means it counteracts the effects of opioid medications. These drugs work together to prevent withdrawal symptoms associated with an opioid addiction

The global suboxone market is estimated to be valued at US$ 6,163.9 million in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030).

Figure 1.Global Suboxone Market Share (%) in Terms of Value, by Type, 2022

Suboxone  | Coherent Market Insights

The increasing use of opioids is expected to drive growth of the global Suboxone market

Suboxone is a prescription medication used in treating the people who are addicted to opioids. Opioids are powerful pain killers that are highly addictive. Thus, increasing use of opioids is expected to increase demand for suboxone for the treatment of opioid addiction, thereby, driving the growth of the market over the forecast period. For instance, according to the data published by Substance Abuse and Mental Health Services Administration, the agency within the U.S. Department of Health and Human Services, in October 2021, among people aged 12 or older in 2020, 3.4% (or 9.5 million people) misused opioids in the past year (2019) in the U.S. Among the 9.5 million people who misused opioids in 2019, 9.3 million people misused prescription pain relievers and 902,000 people used heroin in the U.S.

CMI table icon

Suboxone Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 6,163.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.0% 2030 Value Projection: US$ 8,410.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Branded, Generics
  • By Formulation: Tablets, Films
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Indivior PLC, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Rhodes Pharmaceuticals L.P., Alvogen, Sun Pharmaceutical Industries Ltd., Alkem Labs, and Hikma Pharmaceuticals PLC

Growth Drivers:
  • Increasing use of opioids
  • Rising prevalence of chronic and acute pain
  • Increasing approvals and launches for generic versions of suboxone
Restraints & Challenges:
  • Product recalls
  • Side effects associated with the use of suboxone

Figure 2.Global Suboxone Market Share (%), by Formulation, 2022

Suboxone  | Coherent Market Insights

Increasing approvals and launches for generic versions of suboxone is expected to drive the market growth during the forecast period.

The increasing regulatory approvals and launches for generic versions of suboxone is expected to drive the market growth during the forecast period. For instance, in 2020, the U.S. Food and Drug Administration (FDA) approved a generic drug buprenorphine and naloxone tablet developed by Rhodes Pharmaceuticals, a subsidiary of Purdue, an American privately held pharmaceutical company.

Global Suboxone Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus or COVID-19 outbreak was started in Wuhan, China in 2019 and spread across all the continents of the world, affecting various industries globally. The economies of countries all over the world, such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others, have been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sectors that has been majorly impacted by the pandemic.

However, according to an article published by the American Society of Addiction Medicine, a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine, in November 2020, the anxiety and stress associated with the COVID-19 pandemic, increased the demand for buprenorphine in patients with opioid addiction in the U.S.

Therefore, the demand for suboxone in COVID-19 pandemic increased but the supply was hampered due to lockdowns and COVID-19 restrictions.

Global Suboxone Market: Restraint

The major factors that hinder growth of the global suboxone market include product recalls and side effects associated with suboxone. For instance, Alvogen, an American pharmaceuticals company recalled a single lot of buprenorphine and naloxone sublingual films because of subpotency, according to the July 14, 2021, the U.S. Food and Drug Administration (FDA) Enforcement Report.

Key Players

Major players operating in the global suboxone market include Indivior PLC, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Rhodes Pharmaceuticals L.P., Alvogen, Sun Pharmaceutical Industries Ltd., Alkem Labs, and Hikma Pharmaceuticals PLC

Suboxone is a prescription opioid medication that is used to inhibit the effects of opioid medications, such as pain relief, which can lead to opioid dependence. Suboxone can be used alone or in combination with other drugs to treat opioid addiction. Suboxone belongs to a drug class known as opioid antagonists, analgesics, and opioid partial agonists. Suboxone is composed of buprenorphine and naloxone. Buprenorphine is an opioid medicine, sometimes known as a narcotic. Naloxone counteracts the benefits of opioid medications, such as pain relief and feelings of well-being, which can lead to opioid dependence.

Market Dynamics

The increasing product launches for suboxone is expected to drive the growth of global suboxone market over the forecast period. In September 2018, Lannett Co Inc., a global manufacturer of pharmaceutical products, launched five products that include Buprenorphine plus Naloxone Sublingual tablets, and others.

Moreover, increasing prescription of opioids in certain regions is expected to drive the market growth over the forecast period. For instance, a research published by EclinicalMedicine, a new open access clinical journal, in November 2021 stated that the U.K. had the highest consumption rate of prescription opioids for pain management per capita in the world, despite declining rates globally.

Furthermore, increasing prevalence of chronic pain is expected to drive the growth of global suboxone market over the forecast period. For instance, according to data published by Centers for Disease Control and Prevention in September 2018, stated that an estimated 20.4% of the U.S. adults (50.0 million) had chronic pain and 8.0% of the U.S. adults (19.6 million) had high-impact chronic pain with higher prevalence associated with advancing age in 2016.

Key features of the study:

  • This report provides an in-depth analysis of the global suboxone market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global suboxone market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Indivior PLC, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Rhodes Pharmaceuticals L.P., Alvogen, Sun Pharmaceutical Industries Ltd., Alkem Labs, and Hikma Pharmaceuticals PLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global suboxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global suboxone market

Detailed Segmentation:

  • Global Suboxone Market, By Type:
    • Branded
    • Generics
  • Global Suboxone Market, By Formulation:
    • Tablets
    • Films
  • Global Suboxone Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Suboxone Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Indivior PLC.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Reddy’s Laboratories Ltd.
    • Amneal Pharmaceuticals LLC.
    • Mylan N.V.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Mallinckrodt
    • Lannett Co Inc.
    • Rhodes Pharmaceuticals L.P.
    • Alvogen
    • Sun Pharmaceutical Industries Ltd.
    • Alkem Labs
    • Hikma Pharmaceuticals PLC

“*” marked represents similar segmentation in other categories in the respective section

Frequently Asked Questions

The global suboxone market size is estimated to be valued at US$ 6,163.9 million in 2022 and is expected to exhibit a CAGR of 4.0% between 2022 and 2030.
Factors such as increasing use of opioids, rising prevalence of chronic and acute pain, and increasing approvals and launches for generic versions of suboxone are expected to drive the growth of the market during the forecast period.
Generics segment is the leading type segment in the market
The major factors hampering growth of the market include product recalls and side effects associated with the use of suboxone.
Major players operating in the market include Indivior PLC, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., Mallinckrodt, Lannett Co Inc., Rhodes Pharmaceuticals L.P., Alvogen, Sun Pharmaceutical Industries Ltd., Alkem Labs, and Hikma Pharmaceuticals PLC

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo